Sunitinib in Recurrent, Refractory, or Progressive High Grade Glioma and Ependymoma Tumors

Children's Oncology Group (COG)


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory, or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients

What is the trial about?

Effects sunitinib has on children and young adults with recurrent, progressive, or refractory high-grade glioma or ependymoma brain tumors.

Who can participate?

> 18 months and < 22 yrs of age.

What is involved?

Length of study up to 2 years. Standard cancer care.

Contact Nemours Clinical Trials

Trial Name: A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory, or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients

COG#: ACNS1021

Contact Information

(800) 354-5690
clinicaltrials@nemours.org